Join
Live feed
·
PRReleasevia Quantisnow
MoonLake Immunotherapeutics logo

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
MLTX· MoonLake Immunotherapeutics
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MLTX (MoonLake Immunotherapeutics) and more on Quantisnow.